SCHEMBL5580122

SCHEMBL5580122

CC(CO)CCC(O)n1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CYP3A4 P08684 1/20 0.51
NFKB1 P19838 1/20 0.51
VCP P55072 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HIF1A Q16665 1/20 0.51
HPRT1 P00492 6/20 0.50
TK1 P04183 2/20 0.48
HBB P68871 2/20 0.47
PNP P00491 2/20 0.47
USP2 O75604 1/20 0.47
TSHR P16473 1/20 0.47
EDNRA P25101 1/20 0.47
HTR2A P28223 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7815960 0.85 HPRT1 (0.54) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL8896807 0.85 HPRT1 (0.52) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL6455102 0.84 HPRT1 (0.56) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL28066642 0.83 HPRT1 (0.56) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL19662085 0.83 HPRT1 (0.56) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL7752187 0.82 BLM (0.54) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL10015780 0.81 TK1 (0.66) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL10018373 0.81 MEN1 (0.55) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL8493226 0.80 HPRT1 (0.54) BLMMEN1KMT2AALDH1A1LMNA
SCHEMBL19050063 0.80 MEN1 (0.57) BLMMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032446-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2007-02-08 US disclosed
US-20060270624-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
EP-1695979-A2 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2006-08-30 EP disclosed
EP-1044987-B1 Gapped 2'-modified oligonucleotides ISIS PHARMACEUTICALS INC (US) 2006-02-15 EP disclosed
US-20050112563-A9 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2005-05-26 US disclosed
US-20040038274-A1 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2004-02-26 US disclosed
US-20020160379-A1 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-31 US disclosed
US-6326199-B1 Gapped 2′ modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2001-12-04 US disclosed
EP-0618925-B1 ANTISENSE OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2001-08-29 EP disclosed
US-6146829-A MODIFYING RNA IN TEST SOLUTION CONTAINING RNASE HI BY HYBRIDIZING WITH OLIGONUCLEOTIDE HAVING NUCLEOTIDES WITH 2'DEOXY-ERYTHRO-PENTOFURANOSYL SUGAR MOIETIES; ACTIVATES RNASE AND RESISTS NUCLEASE DEGRADATION ISIS PHARMACEUTICALS, INC. (US) 2000-11-14 US disclosed
EP-1044987-A2 Gapped 2'-modified oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2000-10-18 EP disclosed
US-5856455-A INCREASED NUCLEASE RESISTANCE; ATLEAST ONE NUCLEOTIDE UNIT BEARS AMINOALKOXY, ALLYLOXY, OR IMIDAZOLYLALKOXY 2'-SUBSTITUENT GROUP AND PLURITY OF NUCLEOTIDE GROUP HAVE 2'-DEOXY-ERYTHROPENTOFURANOSYL SUGAR UNITS ISIS PHARMACEUTICALS, INC. (US) 1999-01-05 US disclosed
US-5623065-A MODIFIED OLIGONUCLEOTIDE WHICH HAS BINDING AFFINITY TO COMPLEMENTARY NUCLEIC ACID, INHIBITS TRANSLOCATION OF SAID ACID, PROMOTES RIBONUCLEASE CLEAVAGE IN VITRO ISIS PHARMACEUTICALS, INC. (US) 1997-04-22 US disclosed
EP-0618925-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1994-10-12 EP disclosed
WO-1993013121-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1993-07-08 WO disclosed